Convergence Financial LLC Sells 5,146 Shares of Johnson & Johnson $JNJ

Key Points

• Convergence Financial LLC cut its Johnson & Johnson stake by 54.6% in the third quarter, selling 5,146 shares and retaining 4,282 shares valued at approximately $1.13 million.
• Other institutional investors increased their J&J holdings, and institutions collectively own 69.55% of the stock. The company recently reported quarterly EPS of $2.59, ahead of the $2.53 consensus estimate, with revenue up 5.9% year over year.
• J&J shares were trading near their 52-week high at $273.39, while analysts maintained a generally favorable “Moderate Buy” consensus with an average price target of $275.92. The company also declared a quarterly dividend of $1.34 per share, representing a 2.0% yield.

Convergence Financial LLC reduced its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 54.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,282 shares of the company's stock after selling 5,146 shares during the period. Convergence Financial LLC's holdings in Johnson & Johnson were worth $1,134,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in JNJ. Petersen Hastings Wealth Advisors Inc. boosted its holdings in shares of Johnson & Johnson by 9.7% in the 3rd quarter. Petersen Hastings Wealth Advisors Inc. now owns 1,304 shares of the company's stock worth $345,000 after acquiring an additional 115 shares in the last quarter. William Mack & Associates Inc. lifted its position in Johnson & Johnson by 4.9% during the 3rd quarter. William Mack & Associates Inc. now owns 1,540 shares of the company's stock valued at $408,000 after purchasing an additional 72 shares during the period. Victory Financial Group LLC boosted its stake in Johnson & Johnson by 24.0% in the third quarter. Victory Financial Group LLC now owns 9,130 shares of the company's stock valued at $2,417,000 after acquiring an additional 1,769 shares during the last quarter. Great Lakes Retirement Inc. grew its stake in shares of Johnson & Johnson by 7.4% during the third quarter. Great Lakes Retirement Inc. now owns 8,783 shares of the company's stock worth $2,325,000 after purchasing an additional 603 shares during the period. Finally, IMG Wealth Management Inc. increased its stake in shares of Johnson & Johnson by 1.2% in the 3rd quarter. IMG Wealth Management Inc. now owns 3,665 shares of the company's stock valued at $970,000 after acquiring an additional 45 shares during the last quarter. 69.55% of the stock is owned by institutional investors.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Icotyde, J&J’s oral plaque-psoriasis treatment, is reportedly gaining traction among U.S. dermatologists and being prescribed earlier in the treatment process. Strong adoption could support pharmaceutical growth and help offset declines in older products. Does Johnson & Johnson Have a New Edge in Plaque Psoriasis?
• Positive Sentiment: J&J presented 26 abstracts at TCT 2026 supporting the safety, efficacy and cost-effectiveness of its Impella heart pumps. The data may strengthen the long-term outlook for the MedTech portfolio despite recent weakness. Johnson & Johnson Presents Impella Data at TCT 2026
• Positive Sentiment: J&J continues to be highlighted as a dependable dividend stock, supported by more than five decades of annual payout increases. That income profile can provide downside support for long-term investors. Dividend Kings With 50-Plus Years of Payout Increases
• Neutral Sentiment: J&J’s recent performance has been strong, with shares reportedly up 42% over the past year, helped by progress toward resolving talc litigation and growth from newer medicines. Analysts are debating whether that advance has already priced in much of the improvement. Johnson & Johnson Is Up 42% in a Year
• Neutral Sentiment: Broker sentiment remains generally favorable, but the article questions how much weight investors should place on consensus recommendations as J&J trades near its 52-week high and at an elevated earnings multiple. Johnson & Johnson Broker Ratings
• Negative Sentiment: MedTech growth slowed in the third quarter because of international-market challenges and weakness at Abiomed. Investors may be concerned that a rebound in the fourth quarter will not fully offset the segment’s short-term disappointment. JNJ MedTech Segment Disappoints in Q3
• Negative Sentiment: Analysts see potential earnings pressure in 2027, while the market is already assigning a premium valuation after strong gains. That combination increases the risk of profit-taking if growth slows. Johnson & Johnson Strong Q3 Growth, but 2027 Could Test Earnings
• Negative Sentiment: Pomerantz announced an investigation into potential claims on behalf of J&J investors. Although such announcements do not establish wrongdoing, they add headline and litigation risk. Pomerantz Investor Investigation

Analyst Ratings Changes

Several brokerages recently commented on JNJ. Bank of America reaffirmed a "neutral" rating and set a $278.00 price objective on shares of Johnson & Johnson in a research note on Tuesday, September 29th. Wall Street Zen downgraded Johnson & Johnson from a "buy" rating to a "hold" rating in a research note on Saturday, August 1st. Freedom Capital raised Johnson & Johnson from a "hold" rating to a "strong-buy" rating in a report on Thursday, July 16th. Stifel Nicolaus set a $260.00 price objective on Johnson & Johnson in a report on Wednesday, July 15th. Finally, Johnson Rice lowered shares of Johnson & Johnson from a "buy" rating to a "hold" rating in a research report on Wednesday, October 21st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $275.92.

Johnson & Johnson Price Performance

JNJ stock opened at $273.39 on Friday. The company's 50-day moving average is $265.74 and its 200-day moving average is $246.94. The stock has a market capitalization of $658.13 billion, a PE ratio of 41.42, a price-to-earnings-growth ratio of 2.72 and a beta of 0.21. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 0.74. Johnson & Johnson has a 1 year low of $185.12 and a 1 year high of $282.02.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The firm had revenue of $25.40 billion during the quarter, compared to the consensus estimate of $25.38 billion. During the same quarter in the previous year, the company posted $2.80 earnings per share. The company's quarterly revenue was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Equities research analysts expect that Johnson & Johnson will post 11.12 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be issued a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson's payout ratio is currently 81.21%.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the transaction, the executive vice president owned 25,447 shares of the company's stock, valued at $6,991,308.78. This trade represents a 56.90% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Elizabeth Forminard sold 15,918 shares of the company's stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $257.00, for a total value of $4,090,926.00. Following the completion of the transaction, the executive vice president owned 16,994 shares of the company's stock, valued at $4,367,458. This trade represents a 48.37% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 64,515 shares of company stock valued at $17,271,766. 0.16% of the stock is owned by insiders.

About Johnson & Johnson

Johnson & Johnson NYSE: JNJ is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.